RAC Regulatory Affairs Certification Exam — Questions and Answers

Question 1: Which of the following best describes a 'regulatory gap analysis' in strategic planning?

Evaluating FDA inspection gaps in manufacturing sites
Assessing current dossier status against requirements for target markets (Correct answer)
Identifying missing clinical data in published literature
Comparing competitor regulatory filings to identify opportunities

Correct answer: Assessing current dossier status against requirements for target markets

A regulatory gap analysis compares the existing data package against the submission requirements for target regulatory agencies to identify what additional work is needed.

Question 2: Which post-market activity involves systematically searching published literature, clinical registries, and complaint data to identify new safety signals?

Post-Market Clinical Follow-Up (PMCF) (Correct answer)
510(k) substantial equivalence determination
Quality audit
Design history file review

Correct answer: Post-Market Clinical Follow-Up (PMCF)

PMCF is an ongoing process of proactively collecting clinical data from post-market sources—including literature and registries—to identify new safety and performance signals.

Question 3: Which of the following is a proactive PMS data source, as distinguished from a reactive one?

MDRs filed following a patient injury
Literature surveillance reviewing published clinical studies (Correct answer)
Customer complaint records received after a device failure
Regulatory authority safety alerts issued after incidents

Correct answer: Literature surveillance reviewing published clinical studies

Literature surveillance is proactive because it monitors published evidence regardless of whether an adverse event has already occurred with the manufacturer's specific device.

Question 4: Which 21 CFR Part 820 section specifically addresses the requirement to identify, document, validate, and monitor software used as part of production or quality systems?

§820.40 — Document controls
§820.250 — Statistical techniques
§820.70(i) — Automated processes (Correct answer)
§820.30 — Design controls

Correct answer: §820.70(i) — Automated processes

§820.70(i) requires validation of software used in production or quality systems, including establishing protocols for changes to that software.

Question 5: Under ICH E6(R2) Good Clinical Practice guidelines, what is the sponsor's primary responsibility regarding an Investigational Medicinal Product (IMP)?

Ensuring the IMP is manufactured, handled, and stored in accordance with applicable GMP and used in accordance with the approved protocol (Correct answer)
Conducting all site monitoring visits personally
Recruiting and enrolling all study subjects
Designing the statistical analysis plan for the trial

Correct answer: Ensuring the IMP is manufactured, handled, and stored in accordance with applicable GMP and used in accordance with the approved protocol

ICH E6(R2) places responsibility on the sponsor for ensuring proper GMP manufacture, appropriate handling/storage, and protocol-compliant use of the IMP.

Question 6: Which premarket pathway is specifically intended for devices that treat or diagnose diseases affecting fewer than 8,000 patients per year in the US?

De Novo
PMA
HDE (Correct answer)
Breakthrough Device Designation

Correct answer: HDE

The Humanitarian Device Exemption (HDE) is for devices targeting rare diseases or conditions affecting ≤8,000 US patients annually.

Question 7: What is the primary purpose of a Regulatory Affairs Strategic Plan (RASP)?

To outline regulatory milestones, resources, and risk mitigation for product development (Correct answer)
To serve as the product labeling master document
To document all adverse events during clinical trials
To replace the Quality Management System during development

Correct answer: To outline regulatory milestones, resources, and risk mitigation for product development

A RASP aligns regulatory activities with business objectives by defining milestones, resource needs, and contingency strategies throughout development.

Question 8: When developing a regulatory strategy, what is the primary purpose of pre-submission meetings and other formal interactions with health authorities?

To gain clarity on regulatory expectations, obtain guidance on the development plan, and de-risk the submission process. (Correct answer)
To receive informal, non-binding feedback from competitors about the development plan.
To obtain a binding guarantee of product approval before submitting the formal application.
To negotiate lower user fees for the marketing application review.

Correct answer: To gain clarity on regulatory expectations, obtain guidance on the development plan, and de-risk the submission process.

Formal interactions with health authorities, such as pre-submission meetings, are a critical component of regulatory strategy. Their main purpose is to allow sponsors to present their development plan and receive feedback, ask specific questions, and gain alignment on key issues before a formal marketing application is submitted. This proactive communication helps to identify and mitigate potential hurdles, clarify regulatory expectations, and ultimately reduce the risk of major delays or rejection during the review process.

Question 9: A company receives a 'Not Substantially Equivalent' (NSE) decision on its 510(k). What is the NEXT regulatory option to pursue US market authorization?

File a De Novo request or pursue PMA (Correct answer)
Request a 510(k) waiver
Submit an IDE application
Resubmit the same 510(k) without changes

Correct answer: File a De Novo request or pursue PMA

After an NSE decision, the sponsor may file a De Novo request if appropriate classification as Class II is possible, or pursue PMA for Class III.

Question 10: Which of the following statements BEST distinguishes the Premarket Approval (PMA) pathway from the 510(k) pathway?

A 510(k) results in an 'approval' letter, while a PMA results in a 'clearance' letter.
The PMA pathway requires a demonstration of safety and effectiveness through clinical data, whereas a 510(k) relies on substantial equivalence to a predicate. (Correct answer)
510(k) submissions are only for Class I devices, while PMA submissions are for Class II and III devices.
The standard review timeline for a 510(k) is 180 days, whereas for a PMA it is 90 days.

Correct answer: The PMA pathway requires a demonstration of safety and effectiveness through clinical data, whereas a 510(k) relies on substantial equivalence to a predicate.

The fundamental difference lies in the evidence required. The PMA process requires manufacturers to provide valid scientific evidence, typically including clinical trial data, to independently demonstrate a reasonable assurance of the device's safety and effectiveness. In contrast, the 510(k) pathway requires a demonstration of substantial equivalence to a legally marketed predicate device, leveraging the predicate's established safety and effectiveness profile.

Question 11: Which statement correctly describes the relationship between GMP and validation?

Validation activities are optional if process analytical technology is used
Validation replaces the need for in-process testing during routine manufacturing
GMP requires validation only for sterile products
Validation provides documented evidence that GMP processes consistently produce acceptable results (Correct answer)

Correct answer: Validation provides documented evidence that GMP processes consistently produce acceptable results

Validation provides the documented scientific evidence that GMP processes, equipment, and systems consistently produce outcomes meeting predetermined specifications.

Question 12: Which ICH guideline specifically addresses the stability testing of new drug substances and products?

ICH Q10
ICH Q1A(R2) (Correct answer)
ICH Q9
ICH Q8

Correct answer: ICH Q1A(R2)

ICH Q1A(R2) provides guidance on stability testing conditions, protocols, and data interpretation for new drug substances and products.

Question 13: Which document outlines a company's regulatory submission strategy?

Manufacturing plan
Regulatory strategy plan (Correct answer)
Clinical trial protocol
Advertising budget

Correct answer: Regulatory strategy plan

A regulatory strategy plan is a comprehensive document that outlines the specific regulatory pathway, key milestones, timelines, and resources needed to bring a product to market and maintain its compliance throughout its lifecycle. It details how the company will navigate regulatory requirements, manage submissions, and interact with health authorities. This plan serves as a roadmap for all regulatory activities.

Question 14: When a regulatory agency requests labeling negotiations that could significantly restrict the approved indication, which approach MOST effectively protects the sponsor's position?

Present a counter-proposal supported by robust clinical data analyses and a clear benefit-risk argument (Correct answer)
Escalate the dispute directly to the agency's Office of the Commissioner
Accept all agency-proposed label language to ensure approval speed
Withdraw and resubmit with a narrower indication from the outset

Correct answer: Present a counter-proposal supported by robust clinical data analyses and a clear benefit-risk argument

A data-supported counter-proposal demonstrates scientific rigor and provides the agency with evidence-based rationale, giving the strongest basis for negotiating a broader label.

Question 15: Which FDA program allows manufacturers to submit a single, modular PMA application in separate sections as data becomes available?

Staged PMA Review
Modular PMA Program (Correct answer)
Rolling Submission Program
Pre-Submission (Q-Sub) Program

Correct answer: Modular PMA Program

The Modular PMA Program allows sponsors to submit completed modules of a PMA sequentially, enabling concurrent FDA review.

Question 16: Under the ICH E2A guideline, which term describes an adverse event that is unexpected, serious, and reasonably associated with the investigational product?

Adverse Event of Special Interest (AESI)
Serious Adverse Event (SAE)
Suspected Unexpected Serious Adverse Reaction (SUSAR) (Correct answer)
Adverse Drug Reaction (ADR)

Correct answer: Suspected Unexpected Serious Adverse Reaction (SUSAR)

A SUSAR is a serious adverse reaction that is both unexpected (not in the IB) and causally suspected to be related to the investigational product, requiring expedited reporting.

Question 17: In regulatory strategic planning for a new molecular entity (NME), the end-of-Phase 2 (EOP2) meeting is critical primarily because:

It finalizes the product label language
It aligns the Phase 3 program design with FDA's requirements before committing major resources (Correct answer)
It triggers automatic Priority Review designation
FDA approval is granted at this meeting if Phase 2 data are positive

Correct answer: It aligns the Phase 3 program design with FDA's requirements before committing major resources

The EOP2 meeting allows sponsors to confirm that Phase 3 design, endpoints, and statistical approach meet FDA's requirements before investing in expensive pivotal trials.

Question 18: Which GMP requirement specifically addresses the need for written procedures for the receipt, identification, storage, and testing of components?

21 CFR 211.80 (Correct answer)
21 CFR 211.192
21 CFR 211.165
21 CFR 211.100

Correct answer: 21 CFR 211.80

21 CFR 211.80 through 211.94 cover the written procedures and controls required for receipt, identification, storage, handling, sampling, testing, and approval of components.

Question 19: Under 21 CFR Part 314 for NDAs, which labeling revision process allows a manufacturer to implement a minor labeling change without any FDA notification?

Annual Report changes for minor editorial or formatting corrections that do not affect content (Correct answer)
Prior Approval Supplement (PAS) for minor typographical corrections
Field Alert Report for labeling changes related to distributed product
CBE-30 for adding a new indication to the label

Correct answer: Annual Report changes for minor editorial or formatting corrections that do not affect content

Purely editorial or formatting changes that do not alter meaning may be reported in the Annual Report rather than requiring a supplement submission.

Question 20: When a regulatory strategy calls for pursuing Priority Review in the US, what additional planning is required compared to Standard Review?

Additional nonclinical toxicology studies beyond what Standard Review requires
More intensive FDA meeting interactions and readiness for a 6-month rather than 12-month review clock (Correct answer)
Filing of a separate Priority Review application distinct from the NDA/BLA
Submission of a Risk Evaluation and Mitigation Strategy (REMS) before filing

Correct answer: More intensive FDA meeting interactions and readiness for a 6-month rather than 12-month review clock

Priority Review compresses FDA's review goal to 6 months (versus 10-12 for Standard), requiring the regulatory team to be prepared for faster agency feedback cycles and accelerated internal decision-making.

Question 21: When FDA issues an 'Additional Information' (AI) request during a 510(k) review, what happens to the review clock?

FDA has 45 days to review the response
It continues running uninterrupted
It is suspended until the sponsor responds (Correct answer)
It resets to day 1

Correct answer: It is suspended until the sponsor responds

The review clock is placed on hold (suspended) while FDA awaits the sponsor's response to an AI request.

Question 22: Which of the following activities is the BEST example of proactive post-market surveillance?

Investigating a customer complaint about a device failure.
Conducting a customer survey to gather data on device usability and performance in a real-world setting. (Correct answer)
Issuing a field safety corrective action to address a known product defect.
Submitting a vigilance report to a competent authority after a serious injury.

Correct answer: Conducting a customer survey to gather data on device usability and performance in a real-world setting.

Proactive post-market surveillance involves activities initiated by the manufacturer to actively search for information about a device's performance, rather than waiting for events to be reported. A customer survey is a method of actively seeking out this information. Investigating complaints, submitting vigilance reports, and issuing corrections are all reactive measures taken in response to an identified issue or event.

Question 23: The FDA's 'Accelerated Approval' pathway allows approval based on:

Manufacturing process data alone without clinical trials
Compassionate use data from individual patients
Foreign approval by EMA or Health Canada
A surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit (Correct answer)

Correct answer: A surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit

Accelerated Approval allows use of surrogate or intermediate clinical endpoints reasonably likely to predict clinical benefit, with post-approval confirmatory trials required.

Question 24: A PMA supplement that involves a new indication for use but uses the same basic device design is classified as which supplement type?

180-Day Supplement
Panel-Track Supplement (Correct answer)
Real-Time Supplement
Special PMA Supplement

Correct answer: Panel-Track Supplement

Panel-Track Supplements are required when a new indication or labeling change involves clinical data review, often by an advisory panel.

Question 25: A PMA applicant is required to submit a post-approval study. Where is this requirement typically documented?

In the PMA approval order conditions (Correct answer)
In the IDE application
In the 510(k) clearance letter
In the manufacturer's quality manual

Correct answer: In the PMA approval order conditions

Post-approval study requirements are specified as conditions in FDA's PMA approval order, binding the manufacturer to conduct the study.

Question 26: Under 21 CFR Part 803, which type of report must a device manufacturer submit to FDA within 30 calendar days of becoming aware of an event?

MDR for malfunction that could cause serious injury if it recurs (Correct answer)
Annual product report
Field safety corrective action report
Periodic safety update report

Correct answer: MDR for malfunction that could cause serious injury if it recurs

21 CFR 803.50 requires manufacturers to submit an MDR within 30 days for malfunctions that, if they were to recur, could cause or contribute to a serious injury.

Question 27: The systematic collection and analysis of real-world data from post-market surveillance serves as a primary input for the continuous update of which other key quality system process?

Management Review
Supplier Controls
Risk Management (Correct answer)
Design Controls

Correct answer: Risk Management

Post-market surveillance is a critical input to the risk management process, as described in ISO 14971. Data gathered from the market is used to review and update the risk management file, confirming that risk controls are effective and identifying any new hazards. This creates a continuous feedback loop, ensuring the risk profile of the device remains accurate throughout its lifecycle.

Question 28: When must a sponsor submit a Safety Report (IND Safety Report) to the FDA during clinical trials?

Only at the end of the trial
Within 7 or 15 calendar days for serious unexpected suspected adverse reactions (SUSARs) (Correct answer)
Only when the FDA requests it
Annually, with the IND Annual Report

Correct answer: Within 7 or 15 calendar days for serious unexpected suspected adverse reactions (SUSARs)

Fatal or life-threatening unexpected SUSARs must be reported within 7 calendar days; other serious unexpected SUSARs within 15 calendar days.

Question 29: Which of the following is NOT a recognized type of 510(k) submission?

Traditional 510(k)
Expedited 510(k) (Correct answer)
Abbreviated 510(k)
Special 510(k)

Correct answer: Expedited 510(k)

The three recognized 510(k) types are Traditional, Abbreviated, and Special; 'Expedited' is not an official 510(k) category.

Question 30: Under ICH E6(R2) Good Clinical Practice, which document serves as the primary regulatory reference for labeling investigational medicinal products in clinical trials?

The Investigator's Brochure, which contains the clinical and nonclinical data about the investigational product (Correct answer)
The sponsor's internal formulation development report
The clinical study report from the most recent Phase II trial
The approved package insert from any previously approved version of the compound

Correct answer: The Investigator's Brochure, which contains the clinical and nonclinical data about the investigational product

ICH E6(R2) designates the Investigator's Brochure as the key reference document for IMP labeling and the basis for the reference safety information.

Question 31: What is required for an NDA/BLA applicant to use rolling review?

The applicant must have a PDUFA agreement in place
The product must be a generic drug
The product must be marketed in at least one foreign country
The product must have received a qualifying designation such as Fast Track, BTD, or Accelerated Approval (Correct answer)

Correct answer: The product must have received a qualifying designation such as Fast Track, BTD, or Accelerated Approval

Rolling review is available to products with Fast Track, Breakthrough Therapy, or similar qualifying designations, allowing FDA to review completed sections as they are submitted.

Question 32: Which document in a device's technical file summarizes conclusions from postmarket surveillance data and updates the benefit-risk determination?

Post-Market Surveillance Report (PMSR)
Post-Market Clinical Follow-up (PMCF) Plan
Summary of Safety and Clinical Performance (SSCP)
Periodic Safety Update Report (PSUR) (Correct answer)

Correct answer: Periodic Safety Update Report (PSUR)

The PSUR synthesizes PMS data findings and updates the benefit-risk determination for the device on a periodic basis.

Question 33: Under 21 CFR Part 314, what is the standard FDA review clock for a standard NDA?

6 months
18 months
10 months (Correct answer)
12 months

Correct answer: 10 months

FDA's standard review goal for a standard NDA is 10 months from the date of filing.

Question 34: Under FDA's 522 Postmarket Surveillance Order authority, which device characteristic most often triggers a mandatory postmarket surveillance study order?

Class I devices cleared through the 510(k) pathway
Any OTC device sold to consumers without a prescription
Devices marketed exclusively outside the United States
Implanted for more than one year or used in life-supporting applications (Correct answer)

Correct answer: Implanted for more than one year or used in life-supporting applications

FDA issues 522 orders primarily for devices that are implanted, life-supporting, or life-sustaining, or where failure could cause serious adverse health consequences.

Question 35: What is the primary goal of Phase 1 clinical trials?

Evaluate marketing strategies
Gather long-term outcome data
Compare efficacy with existing drugs
Assess safety and dosing (Correct answer)

Correct answer: Assess safety and dosing

Phase 1 clinical trials are the first stage of testing a new drug in humans, typically involving a small group of healthy volunteers or patients with the target condition. The primary goal is to assess the drug's safety, determine a safe dosage range, and understand how the drug is metabolized and excreted (pharmacokinetics). Efficacy is not the main focus at this early stage.

Question 36: Under GMP, when is a written deviation report required?

When an unexpected departure from an approved procedure occurs (Correct answer)
Only for deviations discovered by FDA inspectors
Only when product is released to market
When a batch fails final release testing

Correct answer: When an unexpected departure from an approved procedure occurs

Any unexpected departure from an approved procedure during manufacturing must be documented in a deviation report to maintain GMP compliance and traceability.

Question 37: Which of the following best describes an FDA Advisory Committee meeting?

A public meeting where independent experts provide non-binding recommendations to FDA (Correct answer)
A binding vote that FDA must follow to approve or reject a product
A mandatory step for all NDA/BLA submissions
A closed hearing where only the applicant and FDA attend

Correct answer: A public meeting where independent experts provide non-binding recommendations to FDA

Advisory Committee meetings bring together independent scientific experts to provide non-binding recommendations; FDA considers but is not required to follow the committee's vote.

Question 38: When building a regulatory strategy for a pediatric indication, which US regulatory requirement must be considered from early development?

The Pediatric Research Equity Act (PREA) may require pediatric studies as part of the application (Correct answer)
Pediatric studies are only required after adult approval is obtained
FDA always grants automatic waivers for pediatric requirements in oncology
Pediatric studies are voluntary and do not affect adult approval timelines

Correct answer: The Pediatric Research Equity Act (PREA) may require pediatric studies as part of the application

Under PREA, sponsors of new drugs and biologics for adult indications must assess the product in pediatric populations unless a waiver or deferral is granted.

Question 39: What is the significance of the 'refuse to file' (RTF) decision in NDA/BLA review?

FDA rejects the application permanently
FDA approves the product conditionally
FDA requests additional clinical trials be conducted
FDA determines the application is not sufficiently complete to permit substantive review (Correct answer)

Correct answer: FDA determines the application is not sufficiently complete to permit substantive review

An RTF decision means FDA found the application administratively or scientifically incomplete and will not begin the 10- or 6-month review clock.

Question 40: Which post-market requirement ensures continued compliance with good manufacturing practices?

Annual sales report
Marketing approval
Patent check
FDA inspections and audits (Correct answer)

Correct answer: FDA inspections and audits

FDA inspections and audits are crucial post-market requirements that ensure pharmaceutical manufacturers and medical device companies continue to comply with Good Manufacturing Practices (GMP) and other regulatory standards. These routine or for-cause inspections verify that products are consistently produced and controlled according to quality standards. This ongoing oversight helps maintain product quality and safety after initial marketing approval.

Question 41: A regulatory affairs professional is assessing whether to use FDA's Breakthrough Therapy Designation (BTD). Which criterion is most critical?

Preliminary clinical evidence shows substantial improvement over available therapy for serious conditions (Correct answer)
The drug must have orphan designation already granted
The drug must treat a rare disease with fewer than 200,000 US patients
Phase 3 trials must already be completed

Correct answer: Preliminary clinical evidence shows substantial improvement over available therapy for serious conditions

BTD requires preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over existing therapies on a clinically significant endpoint for serious conditions.

Question 42: A sponsor wants to make a post-approval change to a drug's manufacturing process. Which type of FDA submission is typically required for a major change?

Comparability Protocol
Field Alert Report
Prior Approval Supplement (PAS) (Correct answer)
Annual Report

Correct answer: Prior Approval Supplement (PAS)

A Prior Approval Supplement (PAS) must be submitted and approved by FDA before implementing major post-approval manufacturing changes.

Question 43: What is the significance of a Breakthrough Therapy designation granted by FDA?

It automatically grants marketing approval without further review
It provides more intensive FDA guidance and organizational commitment to expedite development of a drug for serious conditions (Correct answer)
It grants the product seven years of market exclusivity
It waives all Phase 3 clinical trial requirements

Correct answer: It provides more intensive FDA guidance and organizational commitment to expedite development of a drug for serious conditions

Breakthrough Therapy designation provides intensive FDA guidance, senior agency involvement, and rolling review to expedite development of drugs addressing serious unmet needs.

Question 44: Which FDA meeting type is categorized as 'Type B' for drug development?

Post-market surveillance planning meetings
End-of-Phase 2 meetings and pre-NDA/BLA meetings (Correct answer)
Meetings to resolve manufacturing disputes
Meetings requested to discuss labeling post-approval

Correct answer: End-of-Phase 2 meetings and pre-NDA/BLA meetings

Type B meetings include End-of-Phase 2 (EOP2) and pre-NDA/BLA meetings, which are critical milestones in drug development requiring FDA input.

Question 45: A Data Safety Monitoring Board (DSMB) is MOST commonly used in clinical trials to:

Audit CRF data for accuracy
Approve protocol amendments
Certify investigator qualifications
Provide independent interim review of accumulating safety and efficacy data (Correct answer)

Correct answer: Provide independent interim review of accumulating safety and efficacy data

A DSMB independently reviews unblinded interim data to recommend continuation, modification, or early stopping of a trial based on safety or efficacy.

Question 46: In the EU regulatory system, what is the 'centralised procedure' for medicinal product authorisation?

A mutual recognition process between two or more member states without EMA involvement
A single evaluation by the European Medicines Agency (EMA) leading to a marketing authorisation valid in all EU/EEA member states (Correct answer)
A fast-track process exclusively for orphan medicinal products
A procedure where each EU member state independently evaluates and approves a product for its own territory

Correct answer: A single evaluation by the European Medicines Agency (EMA) leading to a marketing authorisation valid in all EU/EEA member states

The centralised procedure results in a single EMA opinion and a European Commission decision granting a marketing authorisation valid across all EU and EEA countries.

Question 47: Which internal department is most often engaged during regulatory planning?

Logistics
Finance
Human Resources
Clinical and R&D teams (Correct answer)

Correct answer: Clinical and R&D teams

During regulatory planning, the regulatory affairs department works most closely with clinical and R&D teams because these departments generate the scientific data required for regulatory submissions. Regulatory professionals guide these teams on study design, data collection, and documentation to ensure compliance with regulatory standards. This collaboration is essential for developing a robust regulatory strategy and preparing comprehensive dossiers.

Question 48: What is the role of a Target Product Profile (TPP) in regulatory strategy?

It defines the desired product attributes that drive regulatory, clinical, and CMC development decisions (Correct answer)
It is a required FDA submission document for all INDs
It specifies the drug's chemical synthesis route for manufacturing
It replaces the Risk Management Plan (RMP) in EU submissions

Correct answer: It defines the desired product attributes that drive regulatory, clinical, and CMC development decisions

The TPP articulates the minimum and ideal characteristics of the final product, aligning all development functions — including regulatory — around shared goals from the outset.

Question 49: A product is approved in the US but the sponsor plans EU submission. Which ICH guideline is most relevant for planning additional safety studies to address European requirements?

ICH Q10 (Pharmaceutical Quality System)
ICH E1 (Population Exposure) or ICH S6 for specific product types addressing safety database size (Correct answer)
ICH Q8 (Pharmaceutical Development)
ICH M4 (CTD format)

Correct answer: ICH E1 (Population Exposure) or ICH S6 for specific product types addressing safety database size

ICH E1 addresses the extent of patient exposure needed to assess clinical safety, helping sponsors determine if their US safety database is sufficient for EU submission or if additional data is needed.

Question 50: In strategic planning for a generic drug, which factor most significantly determines the regulatory pathway in the US?

The size of the patient population needing the drug
Whether the active ingredient has been approved in Europe
The brand drug's patent expiration date and market exclusivity status (Correct answer)
The manufacturing site's ISO certification status

Correct answer: The brand drug's patent expiration date and market exclusivity status

Patent expiration and exclusivity periods (including 180-day exclusivity for first filers) are central to determining when and how a generic ANDA can be strategically filed.

Question 51: A manufacturer uses contract manufacturers to produce subassemblies. Under 21 CFR Part 820, the primary manufacturer's obligation regarding these contractors is to:

Establish and maintain procedures to ensure they meet specified requirements (Correct answer)
Audit contractors annually and submit findings to FDA
Register each contractor as a medical device manufacturer
Hold contracts contingent on FDA pre-approval of the contractor facility

Correct answer: Establish and maintain procedures to ensure they meet specified requirements

§820.50 requires establishing procedures to ensure contractors meet specified requirements; the primary manufacturer retains full responsibility for quality system compliance.

Question 52: A regulatory affairs professional discovers a discrepancy between data in a published clinical study report and the submission dossier. What is the FIRST action to take?

Investigate the source of the discrepancy, document findings, and notify appropriate internal stakeholders before determining regulatory action (Correct answer)
Retract the clinical study report and rerun the analysis
Submit a corrective amendment immediately without further investigation
Disregard the discrepancy if it does not affect the primary endpoint

Correct answer: Investigate the source of the discrepancy, document findings, and notify appropriate internal stakeholders before determining regulatory action

Investigating and documenting the discrepancy before taking action ensures the root cause is understood and the appropriate corrective or reporting strategy is implemented.

Question 53: Which action is required when a manufacturer's PMS data shows that a device's benefit-risk profile is no longer acceptable?

Initiate a field safety corrective action and notify relevant competent authorities (Correct answer)
Transfer responsibility to the distributor
Conduct an internal meeting only, with no external notification
Increase marketing efforts to shift perception of the device

Correct answer: Initiate a field safety corrective action and notify relevant competent authorities

When PMS data invalidates the benefit-risk profile, the manufacturer must take a field safety corrective action and report it to regulators as required.

Question 54: Which regulatory framework governs the approval of biosimilar products in the United States?

Food and Drug Administration Safety and Innovation Act (FDASIA)
21st Century Cures Act
Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act)
Biologics Price Competition and Innovation Act (BPCIA) (Correct answer)

Correct answer: Biologics Price Competition and Innovation Act (BPCIA)

The BPCIA, enacted in 2010 as part of the Affordable Care Act, established the abbreviated licensure pathway for biosimilar biological products.

Question 55: When preparing a briefing package for a Pre-Submission (Q-Sub) meeting with the FDA for a new medical device, which of the following is the MOST critical component to include?

A complete list of all anticipated marketing claims.
Specific, forward-looking questions for the agency on which feedback is sought. (Correct answer)
The final, locked-down version of the device's Instructions for Use (IFU).
Detailed financial projections for the first five years.

Correct answer: Specific, forward-looking questions for the agency on which feedback is sought.

The primary purpose of a Q-Submission is to obtain feedback from the agency to guide product development and submission preparation. Therefore, including clear, specific, and well-reasoned questions is the most critical component, as these questions will frame the entire discussion and the feedback provided by the FDA. The other elements, while potentially part of the overall package, are secondary to the core goal of getting answers to specific regulatory, technical, or clinical questions.

Question 56: When should a regulatory strategy be formally reassessed during product development?

At predefined decision points and when significant new data emerge (Correct answer)
Annually regardless of development milestones
Only at NDA/BLA submission
Only when FDA issues a complete response letter

Correct answer: At predefined decision points and when significant new data emerge

Regulatory strategy should be reassessed at defined decision gates (e.g., end-of-Phase 2) and whenever significant new clinical, safety, or competitive data emerge.

Question 57: What is the key difference between a 'correction' and a 'removal' under FDA's 21 CFR Part 806?

Corrections apply to Class I devices; removals apply to Class III
Corrections require FDA approval; removals do not
Corrections are mandatory; removals are voluntary
Corrections address devices at the point of use or distribution; removals bring devices back to the manufacturer or distributor (Correct answer)

Correct answer: Corrections address devices at the point of use or distribution; removals bring devices back to the manufacturer or distributor

A correction addresses a device problem at its current location, while a removal involves physically returning the device from the field to the manufacturer or distributor.

Question 58: Under EUDAMED, which module is specifically designed to capture vigilance data including serious incident reports and FSCAs?

Actor Registration module
UDI/Device Registration module
Notified Body and Certificates module
Vigilance and Post-Market Surveillance module (Correct answer)

Correct answer: Vigilance and Post-Market Surveillance module

EUDAMED's Vigilance and Post-Market Surveillance module captures serious incident reports, periodic summary reports, and FSCAs from manufacturers.

Question 59: A pharmaceutical sponsor has an active Investigational New Drug (IND) application for a product in Phase 2 clinical trials. According to FDA regulations (21 CFR 312.33), what must the sponsor submit to the FDA within 60 days of the anniversary date of the IND going into effect?

A 15-day Alert Report
A complete Development Safety Update Report (DSUR)
A New Drug Application (NDA)
An IND Annual Report (Correct answer)

Correct answer: An IND Annual Report

Under 21 CFR 312.33, sponsors are required to submit an IND Annual Report to the FDA. This report must be submitted within 60 days of the anniversary of the date the IND went into effect and should summarize the status of ongoing studies, provide a summary of the previous year's findings, and update any new information.

Question 60: A sponsor submits a 505(b)(2) NDA. What distinguishes this pathway from a standard 505(b)(1) application?

It requires no clinical data whatsoever
It bypasses the advisory committee review process
It relies at least in part on data not developed by the applicant, such as published literature or FDA's findings for a previously approved drug (Correct answer)
It is reserved exclusively for generic drug products

Correct answer: It relies at least in part on data not developed by the applicant, such as published literature or FDA's findings for a previously approved drug

A 505(b)(2) NDA allows applicants to rely on data they did not develop, including FDA's prior findings of safety and effectiveness for a referenced drug.

Question 61: During a scheduled management review, the Head of Quality presents data showing a negative trend in supplier performance, specifically an increase in late deliveries of a critical component. According to the Quality System Regulation (21 CFR 820.20), what is the MOST appropriate output of this review?

A directive to the purchasing department to immediately find a new supplier.
A decision to increase the safety stock of the critical component to buffer against late deliveries.
An assignment of an action item to investigate the supplier issue and a commitment of resources to address it. (Correct answer)
A note in the meeting minutes to re-evaluate the trend at the next quarterly review.

Correct answer: An assignment of an action item to investigate the supplier issue and a commitment of resources to address it.

Management review, as defined in 21 CFR 820.20(c), requires reviewing the suitability and effectiveness of the quality system and making decisions or assigning actions where needed. The primary role of management is to assess data and assign actions and resources to ensure the effectiveness of the quality system. Simply finding a new supplier is premature, increasing stock is a temporary fix, and waiting is not proactive.

Question 62: In a pediatric drug development program, what does a Pediatric Study Plan (PSP) require the sponsor to address?

The IND safety reporting schedule for all age groups
Adult Phase 3 trial design and statistical power calculations
Post-market surveillance commitments for adult populations
The studies the sponsor plans to conduct in pediatric populations, relevant timelines, and justification for any waivers or deferrals (Correct answer)

Correct answer: The studies the sponsor plans to conduct in pediatric populations, relevant timelines, and justification for any waivers or deferrals

A PSP outlines the sponsor's plan for studying the drug in relevant pediatric populations, including study designs, age groups, and justification for any requested waivers or deferrals under PREA.

Question 63: Which of the following is the primary EU regulation governing postmarket surveillance for medical devices?

Directive 90/385/EEC (AIMDD)
Regulation (EU) 2017/745 (MDR) (Correct answer)
Regulation (EU) 2017/746 (IVDR)
Directive 93/42/EEC (MDD)

Correct answer: Regulation (EU) 2017/745 (MDR)

EU Regulation 2017/745 (MDR) is the primary regulation governing medical device postmarket surveillance in the EU, replacing MDD.

Question 64: What is the purpose of Risk Evaluation and Mitigation Strategies (REMS)?

Simplify manufacturing
Encourage over-the-counter use
Speed up clinical trials
Ensure safe use of high-risk medications (Correct answer)

Correct answer: Ensure safe use of high-risk medications

Risk Evaluation and Mitigation Strategies (REMS) are programs required by the FDA for certain high-risk medications to ensure that the benefits of the drug outweigh its risks. REMS programs can include elements like patient registries, specialized training for prescribers, or restricted distribution systems. Their primary goal is to mitigate specific serious risks and promote the safe use of these drugs.

Question 65: Under 21 CFR 314.50, what is required to be included in the 'Summary' section (Module 2) of an NDA?

Only the proposed prescribing information and labeling
Raw clinical data tabulations and case report forms
Financial disclosure forms for all clinical investigators
Comprehensive summaries of quality, nonclinical, and clinical data including an integrated benefit-risk assessment (Correct answer)

Correct answer: Comprehensive summaries of quality, nonclinical, and clinical data including an integrated benefit-risk assessment

Module 2 of the CTD/NDA requires structured summaries of quality, nonclinical, and clinical data, culminating in an integrated benefit-risk discussion.

Question 66: A company is planning global market entry for a Class II medical device. Which regulatory pathway typically offers the fastest US market access?

PMA
Humanitarian Device Exemption
De Novo classification
510(k) with predicate (Correct answer)

Correct answer: 510(k) with predicate

A 510(k) submission demonstrating substantial equivalence to a legally marketed predicate device is the fastest pathway for Class II devices.

Question 67: A pharmaceutical company's TV advertisement for a prescription drug uses rapid voice-over to present risk information. Under 21 CFR 202.1(e)(1), what is this technique called and what is FDA's position on it?

FDA allows rapid disclosure as long as the total duration of risk audio exceeds 15 seconds
Rapid voice-over is explicitly permitted under the DTC broadcast ad guidance as a creative technique
The fair balance requirement applies only to print ads, not broadcast media
The 'adequate provision' standard requires that audio risk information be presented in a way that consumers can hear and understand (Correct answer)

Correct answer: The 'adequate provision' standard requires that audio risk information be presented in a way that consumers can hear and understand

FDA's guidance on DTC broadcast advertising requires risk information to be presented in a manner that is understandable to the intended audience, not obscured by speed or technical jargon.

Question 68: What is the MAIN strategic advantage of obtaining Orphan Drug Designation (ODD) for a product intended for a rare disease?

Seven years of market exclusivity upon approval, plus development incentives including tax credits and fee waivers (Correct answer)
Automatic approval without a standard review process
Priority review voucher transferable to another product
Exemption from Phase III clinical trial requirements

Correct answer: Seven years of market exclusivity upon approval, plus development incentives including tax credits and fee waivers

Orphan Drug Designation provides seven years of post-approval market exclusivity and financial incentives such as tax credits on clinical costs and waived user fees.

Question 69: Which of the following BEST describes the role of a Target Product Profile (TPP) in regulatory strategic planning?

It is primarily a marketing document used to secure funding from investors and has minimal impact on regulatory interactions.
It is a legally binding contract submitted to regulatory authorities outlining the final, unchangeable product specifications.
It is a static document created at the end of the development process to summarize the product's final characteristics for labeling.
It is a dynamic, strategic tool that outlines the desired product characteristics to guide development and facilitate alignment with regulatory authorities. (Correct answer)

Correct answer: It is a dynamic, strategic tool that outlines the desired product characteristics to guide development and facilitate alignment with regulatory authorities.

A Target Product Profile (TPP) is a strategic planning tool that outlines the desired characteristics of a product. It is intended to be a 'living document' that evolves as new data becomes available. Its purpose is to guide internal development decisions and facilitate productive discussions with regulatory authorities, ensuring that the development program is aligned with regulatory expectations and clinical needs from an early stage.

Question 70: When a protocol deviation occurs at a site, the investigator's PRIMARY obligation is to:

Notify the FDA within 24 hours
Terminate the affected subject immediately
Amend the protocol retroactively
Document and report the deviation per protocol and IRB requirements (Correct answer)

Correct answer: Document and report the deviation per protocol and IRB requirements

Investigators must document protocol deviations and report them according to the protocol requirements and IRB policies.

Question 71: Which element is NOT a required component of a pharmaceutical quality system under ICH Q10?

Continual improvement of the process
Corrective and preventive action system
Management responsibility
Mandatory third-party audits (Correct answer)

Correct answer: Mandatory third-party audits

ICH Q10 requires management responsibility, CAPA, and continual improvement, but does not mandate third-party audits as a required element.

Question 72: Which element is MANDATORY in a PMS plan according to EU MDR Annex III?

A marketing communication plan for healthcare providers
A list of countries where the device is not yet marketed
A schedule of notified body surveillance audits
A proactive and systematic procedure to collect and review post-market experience (Correct answer)

Correct answer: A proactive and systematic procedure to collect and review post-market experience

EU MDR Annex III requires the PMS plan to specify a proactive, systematic procedure for gathering and reviewing post-market experience from clinical and non-clinical sources.

Question 73: Which provision of the FD&C Act allows FDA to require Risk Evaluation and Mitigation Strategies (REMS) for drugs that pose serious safety risks?

Section 505-1, added by FDAAA 2007 (Correct answer)
Section 351 of the Public Health Service Act
Prescription Drug User Fee Act (PDUFA) Section IV
Section 510(k) of the FD&C Act

Correct answer: Section 505-1, added by FDAAA 2007

Section 505-1 of the FD&C Act, added by the Food and Drug Administration Amendments Act of 2007 (FDAAA), grants FDA authority to require REMS for drugs with serious risks.

Question 74: A medical device manufacturer identifies a software anomaly in its patient monitoring system that may, in rare circumstances, cause a temporary, 5-second data lag. This could theoretically lead to a brief delay in clinical intervention. The manufacturer initiates a voluntary correction. How would the FDA MOST likely classify this recall?

Class I
Market Withdrawal
Class II (Correct answer)
Class III

Correct answer: Class II

A Class II recall applies to situations where the use of a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The scenario describes a potential for temporary harm (delay in intervention), but serious harm is not a reasonable probability, fitting the Class II definition.

Question 75: Which regulatory submission is required when a PMA-approved device manufacturer wants to make a significant change to the device's indication for use?

A Panel-Track Supplement (Correct answer)
A 180-Day Supplement
A Real-Time Supplement
A 30-day notice

Correct answer: A Panel-Track Supplement

Changes to indications for use that require new clinical data are submitted as Panel-Track Supplements, which may be reviewed by an FDA advisory panel.

Question 76: A De Novo request results in which regulatory outcome if granted?

PMA approval
Humanitarian Device Exemption
Class I exemption
Class II classification with special controls (Correct answer)

Correct answer: Class II classification with special controls

A granted De Novo request establishes a new Class II classification with special controls for the device type.

Question 77: What is the primary purpose of a Regulatory Liaison function within a pharmaceutical company?

To serve as the main point of contact managing communication and relationships with regulatory agencies (Correct answer)
To write clinical study protocols
To manage pharmacovigilance reporting obligations exclusively
To perform GMP inspections at contract manufacturers

Correct answer: To serve as the main point of contact managing communication and relationships with regulatory agencies

The Regulatory Liaison function manages ongoing communication, meeting requests, and relationship management with regulatory agencies to ensure productive and consistent interactions.

Question 78: A company's regulatory team must brief senior leadership on a complex FDA response. What is the MOST important principle when communicating technical regulatory information to non-expert executives?

Defer the briefing until all uncertainties are resolved
Use precise regulatory jargon to maintain credibility
Include all raw data tables to ensure completeness
Translate technical findings into business impact language with clear action items (Correct answer)

Correct answer: Translate technical findings into business impact language with clear action items

Effective communication to executives requires framing regulatory information in terms of business risk, timelines, and required decisions rather than technical detail.

Question 79: A medical device manufacturer discovers a recurring nonconformity during in-process testing of a Class II device. According to 21 CFR 820.100, which of the following is the MOST appropriate initial step in the Corrective and Preventive Action (CAPA) process?

Analyzing all relevant quality data to identify the root cause of the nonconformity. (Correct answer)
Immediately scrapping all affected lots of the device.
Disseminating information about the quality problem to all production staff.
Implementing a production-wide change to the manufacturing process.

Correct answer: Analyzing all relevant quality data to identify the root cause of the nonconformity.

According to 21 CFR 820.100(a), the CAPA process requires manufacturers to establish procedures for analyzing various sources of quality data to identify existing and potential causes of nonconforming product. Investigating the cause of the nonconformity is a critical first step before implementing any corrective actions, ensuring that the action taken is effective and appropriate.

Question 80: The concept of 'regulatory intelligence' in strategic planning involves:

Reviewing only published FDA guidance documents quarterly
Monitoring competitor regulatory filings and agency guidance to inform strategy (Correct answer)
Tracking adverse event reports in public databases
Conducting espionage on regulatory agency internal deliberations

Correct answer: Monitoring competitor regulatory filings and agency guidance to inform strategy

Regulatory intelligence involves systematically monitoring regulatory agency activities, competitor filings, guidance documents, and industry trends to inform and update regulatory strategy.

Question 81: A medical device company plans to conduct a clinical study of a novel implantable cardiac defibrillator. The device is intended to sustain human life. According to 21 CFR 812, what is the regulatory status of this investigation and what is required before initiating the study?

Exempt from IDE regulations; no IRB or FDA approval is needed.
Significant risk; both IRB approval and an approved Investigational Device Exemption (IDE) from the FDA are required. (Correct answer)
Non-significant risk; only IRB approval is required.
Significant risk; only an approved IDE from the FDA is required.

Correct answer: Significant risk; both IRB approval and an approved Investigational Device Exemption (IDE) from the FDA are required.

An investigational device that is intended as an implant and presents a potential for serious risk, or is purported to be for use in supporting or sustaining human life, is considered a significant risk (SR) device. Clinical investigations of SR devices require both Institutional Review Board (IRB) approval and an approved Investigational Device Exemption (IDE) from the FDA before the study can begin.

Question 82: Which regulatory strategy principle is illustrated when a company files for orphan drug designation before beginning Phase 3 trials?

Ensuring the drug is exempt from post-market surveillance
Proactive lifecycle planning to secure incentives early in development (Correct answer)
Reactive planning in response to Phase 2 failures
Avoiding the need for clinical trials altogether

Correct answer: Proactive lifecycle planning to secure incentives early in development

Filing for orphan designation proactively secures benefits including market exclusivity, tax credits, and fee waivers before Phase 3 investment, reflecting forward-looking lifecycle strategy.

Question 83: In the context of postmarket compliance, what does 'CAPA' stand for and what is its primary function?

Corrective and Preventive Audit; reviewing quality systems for compliance
Corrective Action and Preventive Action; identifying and eliminating the root causes of nonconformities (Correct answer)
Clinical and Postmarket Assessment; evaluating benefit-risk annually
Compliance Action and Performance Assessment; benchmarking against industry standards

Correct answer: Corrective Action and Preventive Action; identifying and eliminating the root causes of nonconformities

CAPA (Corrective Action and Preventive Action) is a quality system process focused on identifying root causes of nonconformities and preventing their recurrence.

Question 84: In strategic regulatory planning, 'regulatory intelligence' refers to:

AI-based tools that predict approval dates
Competitive intelligence on rival companies' pipelines
Systematic monitoring of agency guidance, decisions, and policy trends to inform strategy (Correct answer)
Background checks on agency reviewers

Correct answer: Systematic monitoring of agency guidance, decisions, and policy trends to inform strategy

Regulatory intelligence involves tracking agency guidance documents, precedent decisions, policy shifts, and advisory committee trends to proactively shape development strategy.

Question 85: When communicating with regulatory agencies, which principle is considered most critical for maintaining a productive long-term relationship?

Submitting only finalized data to avoid preliminary questions
Minimizing all contact with the agency to avoid scrutiny
Consistent transparency and proactive disclosure of relevant issues (Correct answer)
Delegating all agency interactions to external consultants

Correct answer: Consistent transparency and proactive disclosure of relevant issues

Transparency and proactive disclosure build regulatory trust; agencies are more likely to work constructively with sponsors who openly share relevant safety or quality issues early.

Question 86: A sponsor terminates a Phase II trial due to futility. Under 21 CFR 312.38, the sponsor must notify FDA:

Immediately by phone before any written notification
Within 15 days if subjects experienced serious adverse events
Within 30 days of the termination decision (Correct answer)
Only in the annual IND report

Correct answer: Within 30 days of the termination decision

21 CFR 312.38 requires sponsors to notify FDA within 30 days when all clinical investigations under an IND are discontinued.

Question 87: A manufacturer identifies through PMS that a device component is failing at a rate higher than predicted in the design phase. What is the MOST appropriate immediate next step?

Continue selling the current inventory while redesigning the next version
Conduct a root cause analysis and assess whether a CAPA or field action is needed (Correct answer)
Remove the device from the market without notifying competent authorities
Notify the FDA only after 30 days have passed

Correct answer: Conduct a root cause analysis and assess whether a CAPA or field action is needed

Discovering an unexpected failure rate requires root cause analysis and a CAPA assessment to determine if a field safety corrective action is necessary.

Question 88: What is a key feature of effective regulatory communication?

Communicating only after rejection
Relying solely on emails
Clear, accurate, and timely dialogue (Correct answer)
Using technical jargon

Correct answer: Clear, accurate, and timely dialogue

Effective regulatory communication is characterized by clear, accurate, and timely dialogue with regulatory authorities. This approach fosters transparency, builds trust, and facilitates efficient review processes. Proactive and precise communication helps address questions promptly, clarify complex issues, and avoid misunderstandings that could lead to delays or rejections.

Question 89: Under 21 CFR 101.13, which of the following is an 'implied nutrient content claim' requiring compliance with FDA definitions?

A label stating 'Contains Vitamin C' without quantifying the amount
A recipe suggestion on the back panel showing a low-calorie use of the ingredient
The brand name 'Naturals' appearing on a conventional food product
A label depicting a heart symbol next to a low-fat product implying cardiovascular benefit (Correct answer)

Correct answer: A label depicting a heart symbol next to a low-fat product implying cardiovascular benefit

Symbols and logos that characterize the nutrient level of a food constitute implied nutrient content claims under 21 CFR 101.13(b) and must comply with relevant definitions.

Question 90: Which scenario would constitute a 'protocol waiver' rather than a protocol deviation?

A site enrolling a subject outside the enrollment window
Prospective written approval from the sponsor to allow a subject to deviate from a protocol requirement (Correct answer)
A subject missing a single lab visit
A subject taking a prohibited medication without informing the site

Correct answer: Prospective written approval from the sponsor to allow a subject to deviate from a protocol requirement

A waiver is a prospective, sponsor-approved exception to a protocol requirement for a specific subject, whereas a deviation is an unplanned non-compliance.

Question 91: What is the PRIMARY purpose of a regulatory affairs strategic plan document within an organization?

To replace the quality management system for regulatory activities
To serve as the submission dossier for agency review
To document all past regulatory approvals for audit purposes
To outline the regulatory pathway, milestones, risks, and resource requirements for achieving product approval (Correct answer)

Correct answer: To outline the regulatory pathway, milestones, risks, and resource requirements for achieving product approval

A regulatory strategic plan defines the intended approval pathway, key milestones, identified risks, contingency options, and resource needs to guide the development program.

Question 92: What does a Periodic Safety Update Report (PSUR) under EU MDR require for Class IIb devices?

Annual submission
Submission every 5 years
Submission every 3 years
Submission every 2 years (Correct answer)

Correct answer: Submission every 2 years

Under EU MDR, PSURs for Class IIb devices must be submitted to the Notified Body every 2 years.

Question 93: Which metric is MOST useful for tracking the efficiency of a regulatory affairs team's submission planning process over time?

Total pages submitted per application
Cycle time from dossier lock to submission date (Correct answer)
Number of agency meetings attended annually
Number of regulatory staff headcount

Correct answer: Cycle time from dossier lock to submission date

Cycle time from dossier lock to submission measures the internal efficiency of the submission preparation process and can reveal process bottlenecks.

Question 94: Design validation under 21 CFR Part 820 must be performed under which conditions?

Laboratory conditions with accelerated aging
Any conditions defined in the DMR
Simulated or actual use conditions (Correct answer)
Conditions specified by ISO 14971 risk management

Correct answer: Simulated or actual use conditions

§820.30(g) requires design validation to be performed under defined operating conditions on initial production units, lots, or batches, or their equivalents, using simulated or actual use conditions.

Question 95: A company plans to launch its new pharmaceutical product in the United States and the European Union simultaneously. The most effective strategic regulatory planning would involve:

Developing a harmonized development plan that considers the requirements of both the FDA and EMA from the outset. (Correct answer)
Preparing the US submission first and then adapting it for the EU several years later.
Focusing exclusively on the requirements of the larger market and hoping it satisfies the other.
Submitting identical dossiers to both agencies without any country-specific modifications.

Correct answer: Developing a harmonized development plan that considers the requirements of both the FDA and EMA from the outset.

An effective global regulatory strategy involves integrating and harmonizing the requirements of different target regions from the beginning of product development. This proactive approach, often guided by ICH guidelines, helps streamline development, avoid redundant testing, and facilitate more efficient submissions. Simply adapting one region's dossier for another or submitting identical packages is often inefficient and can lead to significant delays or rejection, as specific local requirements would be missed.

Question 96: Which metric is most important to track during strategic regulatory planning to ensure alignment with corporate timelines?

Number of advisory committee meetings attended
Volume of correspondence with FDA
Projected submission date versus regulatory milestone critical path (Correct answer)
Number of regulatory staff headcount per project

Correct answer: Projected submission date versus regulatory milestone critical path

The projected submission date relative to the regulatory critical path determines whether development activities will support corporate launch commitments and revenue projections.

Question 97: During a monitoring visit, a Clinical Research Associate (CRA) compares the data entered into the electronic Case Report Forms (eCRFs) with the original medical records and lab results. This process is known as:

Informed Consent Review
Protocol Amendment Submission
Adverse Event Adjudication
Source Data Verification (SDV) (Correct answer)

Correct answer: Source Data Verification (SDV)

Source Data Verification (SDV) is the process of checking the data transcribed into the Case Report Forms (CRFs) against the original source documents to ensure the data is accurate, complete, and verifiable.

Question 98: Under 21 CFR Part 312, what is the maximum duration of a Phase 1 clinical investigation that can be conducted under an IND before a Phase 2 protocol must be submitted?

There is no specific time limit; Phase 1 can continue as long as needed (Correct answer)
Phase 2 protocol must be submitted before Phase 1 begins
6 months from IND effective date
1 year from IND effective date

Correct answer: There is no specific time limit; Phase 1 can continue as long as needed

The IND regulations do not prescribe a maximum duration for Phase 1; sponsors advance phases based on scientific data and safety findings.

Question 99: A hospital's biomedical engineering department discovers that a ventilator's alarm failed to alert staff, contributing to a patient death. Under MDR regulations, who must report this event to FDA?

Only the attending physician
Only the hospital as a user facility
Both the manufacturer and the hospital as a user facility (Correct answer)
Only the device manufacturer

Correct answer: Both the manufacturer and the hospital as a user facility

Both device manufacturers and user facilities (hospitals) have independent MDR reporting obligations for deaths caused by or suspected to be caused by devices.

Question 100: Under 21 CFR Part 312, a Type B meeting with FDA is most commonly used to discuss:

Post-approval label changes
End-of-Phase 2 issues and pre-NDA/BLA discussions (Correct answer)
REMS program requirements after approval
IND safety reporting procedures

Correct answer: End-of-Phase 2 issues and pre-NDA/BLA discussions

Type B meetings include End-of-Phase 1, End-of-Phase 2, pre-NDA/BLA, and pre-BLA meetings — they are milestone meetings that occur at defined stages of drug development.

RAC Regulatory Affairs Certification Exam

The RAC exam, administered by RAPS, certifies regulatory affairs professionals in their knowledge of strategic planning, pre-marketing, post-marketing, and interfacing with regulatory authorities for drugs and devices.

100

Questions

120 min

Time Limit

75%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds